Compare CAPR & TILE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAPR | TILE |
|---|---|---|
| Founded | 2005 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | CAPR | TILE |
|---|---|---|
| Price | $24.05 | $30.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $41.38 | $32.00 |
| AVG Volume (30 Days) | ★ 1.3M | 321.2K |
| Earning Date | 11-10-2025 | 02-24-2026 |
| Dividend Yield | N/A | ★ 0.26% |
| EPS Growth | N/A | ★ 33.41 |
| EPS | N/A | ★ 1.92 |
| Revenue | $11,130,509.00 | ★ $1,372,471,000.00 |
| Revenue This Year | N/A | $7.55 |
| Revenue Next Year | $16,329.74 | $4.73 |
| P/E Ratio | ★ N/A | $16.10 |
| Revenue Growth | N/A | ★ 5.11 |
| 52 Week Low | $4.30 | $17.24 |
| 52 Week High | $40.37 | $31.35 |
| Indicator | CAPR | TILE |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 62.26 |
| Support Level | $23.53 | $27.81 |
| Resistance Level | $25.44 | $31.35 |
| Average True Range (ATR) | 1.73 | 0.85 |
| MACD | -0.95 | 0.12 |
| Stochastic Oscillator | 12.97 | 69.77 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.